Sex: M
Vaccine: COVID19
Symptoms: Headache, Pain, Pain in extremity, Pruritus, Psoriatic arthropathy
Clinical narrative: Psoriatic arthritis; BODY ACHE; Itching; LITTLE SCALY SKINS; SORE ARM; Headache; This spontaneous case was reported by a consumer and describes the occurrence of PSORIATIC ARTHROPATHY (Psoriatic arthritis) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    Concurrent medical conditions included Psoriasis.   On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced PSORIATIC ARTHROPATHY (Psoriatic arthritis) (seriousness criterion medically significant), PAIN (BODY ACHE), PRURITUS (Itching), SKIN EXFOLIATION (LITTLE SCALY SKINS), PAIN IN EXTREMITY (SORE ARM) and HEADACHE (Headache). At the time of the report, PSORIATIC ARTHROPATHY (Psoriatic arthritis), PRURITUS (Itching) and SKIN EXFOLIATION (LITTLE SCALY SKINS) had not resolved and PAIN (BODY ACHE), PAIN IN EXTREMITY (SORE ARM) and HEADACHE (Headache) had resolved.            No concomitant drug was reported. Skyrizi(risankizumab) was used for the indication of moderate to severe chronic plaque psoriasis. The patient reported that he still had some itching and little scaly skins. He had psoriatic arthritis. He reported that vaccine had caused sore arm, headache and body ache which lasted about 24-48 hours. No treatment drug was reported. Causality for skyrizi(risankizumab): the reporter's causality for the event(s) of itching, psoriatic arthritis, sore arm, little scaly skins, body ache and headache was not provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment: This spontaneous case concerns an elderly male patient with concurrent condition of chronic plaque psoriasis, who experienced the unexpected serious (medically significant) event of Psoriatic arthropathy, unknown days after receiving the first dose of mRNA-1273 vaccine in the COVID-19 vaccination series. The patient received the second dose with the same vaccine as per the recommended schedule. He also had skin exfoliation and pruritus. No information on exact dates of event, detailed clinical course, reports of relevant investigations and treatment details was available in the report. The event had not resolved. Concurrent condition of chronic plaque psoriasis could be a risk factor for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns an elderly male patient with concurrent condition of chronic plaque psoriasis, who experienced the unexpected serious (medically significant) event of Psoriatic arthropathy, unknown days after receiving the first dose of mRNA-1273 vaccine in the COVID-19 vaccination series. The patient received the second dose with the same vaccine as per the recommended schedule. He also had skin exfoliation and pruritus. No information on exact dates of event, detailed clinical course, reports of relevant investigations and treatment details was available in the report. The event had not resolved. Concurrent condition of chronic plaque psoriasis could be a risk factor for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.